A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
Price : $35 *
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Therapeutic Use
- Sponsors GlycoMimetics; Pfizer
- 03 Mar 2015 According to GlycoMimetics media release, results were published in Blood.
- 03 Mar 2015 Results published in the Media Release.
- 10 Dec 2013 Results for the paediatric subgroup presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History